Trial · NCT01617187
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in PANSS Total Score at Day 42 | Baseline and Day 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in CGI-S Score at Day 42 | Baseline and Day 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants Who Are PANSS Responders (≥30% Reduction From Baseline in PANSS Total Score) at Day 42 | Baseline and Day 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Body Weight at Day 42 | Baseline and Day 42 | All randomized participants who received ≥1 dose of study drug | kg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in PANSS Total Score at Days 4, 7, 14, 21, 28 and 35 | Baseline and Days 4, 7, 14, 21, 28 and 35 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants Who Are PANSS Responders (≥30% Reduction From Baseline in PANSS Total Score) at Days 4, 7, 14, 21, 28 and 35 | Days 4, 7, 14, 21, 28 and 35 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in CGI-S Score at Days 4, 7, 14, 21, 28 and 35 | Baseline and Days 4, 7, 14, 21, 28 and 35 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants Who Are Clinical Global Impression Scale-Improvement (CGI-I) Responders at Days 4, 7, 14, 21, 28, 35 and 42 | Days 4, 7, 14, 21, 28, 35 and 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in PANSS Negative Subscale Score at Days 4, 7, 14, 21, 28, 35 and 42 | Baseline and Days 4, 7, 14, 21, 28, 35 and 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in PANSS Positive Subscale Score at Days 4, 7, 14, 21, 28, 35 and 42 | Baseline and Days 4, 7, 14, 21, 28, 35 and 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in PANSS General Psychopathology Subscale Score at Days 4, 7, 14, 21, 28, 35 and 42 | Baseline and Days 4, 7, 14, 21, 28, 35 and 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in PANSS Marder Factor Positive Symptom Score at Days 4, 7, 14, 21, 28, 35 and 42 | Baseline and Days 4, 7, 14, 21, 28, 35 and 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in PANSS Marder Factor Negative Symptom Score at Days 4, 7, 14, 21, 28, 35 and 42 | Baseline and Days 4, 7, 14, 21, 28, 35 and 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in PANSS Marder Factor Disorganized Thought Symptom Score at Days 4, 7, 14, 21, 28, 35 and 42 | Baseline and Days 4, 7, 14, 21, 28, 35 and 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in PANSS Marder Factor Hostility/Excitement Symptom Score at Days 4, 7, 14, 21, 28, 35 and 42 | Baseline and Days 4, 7, 14, 21, 28, 35 and 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in PANSS Marder Factor Anxiety/Depression Symptom Score at Days 4, 7, 14, 21, 28, 35 and 42 | Baseline and Days 4, 7, 14, 21, 28, 35 and 42 | FAS, defined as randomized participants who received ≥1 dose of study drug and had both a baseline and ≥1 post-baseline PANSS Total Score | score on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01617187/outcomes